In order to serve content on our website, we rely on advertising revenue which helps us to ensure that we continue to serve high quality unbiased journalism.
To know how to disable your Ad Blocker, please
Please refresh your page, once Ad Blocker is disabled
Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.
April-June net profit was Rs 13.91 billion ($227.73 million), compared with a net loss of Rs 12.76 billion a year earlier. The prior-year period included a Rs 25.17 billion provision for settlement of a patent infringement litigation.
Analysts on average had expected a profit of Rs 12.85 billion, according to data compiled by Thomson Reuters.
Net sales rose 12% to Rs 39.36 billion, while sales in the United States, from where the company makes more than half its revenue, advanced 7%. Sun Pharma is in the process of gaining regulatory approvals for its $3.2 billion acquisition of loss-making rival Ranbaxy Laboratories Ltd from Japan's Daiichi Sankyo Ltd and expects to close the deal by December.
The company has got approvals for the deal from anti-competition authorities in all applicable markets excluding India and the United States, Sun Pharma said in a statement late on Tuesday.